The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | An update on the ELiPSE-1 study: safety data from patients treated with CNTY-101, a CAR-NK therapy
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, provides an update on the Phase I dose-escalation ELiPSE-1 trial (NCT05336409), which is investigating CNTY-101, an iPSC-derived allogeneic CD19 targeting CAR-NK product, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Dr Patel discusses the safety data from the first 12 patients who received the therapy on one of two dosing schedules. Both efficacy and safety data are promising to date, with low rates of cytokine release syndrome (CRS) and only one patient experiencing immune effector cell-associated neurotoxicity syndrome (ICANS). Dr Patel also highlights that the CAR-NK cells were detected in extravascular spaces, and the first patient treated has shown no evidence of allorejection. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
